Skip to main content

Table 2 Demographic, genetic, and biochemical data in the individual subcohorts

From: Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

 

Total cohort (n = 716)

Cohort 1a (n = 138)

Cohort 1b (n = 72)

Cohort 2 (n = 81)

Cohort 3 (n = 121)

Cohort 4 (n = 39)

Cohort 5 (n = 37)

Cohort 6 (n = 48)

Cohort 7 (n = 58)

Cohort 8 (n = 24)

Cohort 9 (n = 44)

Cohort 10 (n = 54)

Location

 

Gothenburg, Sweden

Gothenburg, Sweden

Perugia, Italy

Stockholm, Sweden

Malmö, Sweden

Malmö, Sweden

Mölndal, Sweden

Kuopio, Finland

Munich, Germany

Stockholm, Sweden

Mölndal, Sweden

Type of clinic

 

Affective disorders clinic

Affective disorders clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Memory clinic

Diagnosis

 

Bipolar disorder

Controls

Controls

Controls

Controls

Controls

Controls

Controls

Controls

Controls

Controls

Age (years), mean (range)

53.3 (17–99)

39.4 (20–73)

37.9 (21–74)

53.0 (21–88)

68.0 (40–92)

72.4 (60–87)

62.9 (42–99)

66.6 (52–80)

65.6 (45–81)

63.0 (49–84)

60.9 (23–88)

22.0 (17–34)

Male, n (%)

305 (42.6)

55 (39.9)

27 (37.5)

22 (27.2)

36 (29.8)

15 (38.5)

16 (43.2)

22 (45.8)

30 (51.7)

15 (62.5)

19 (43.2)

48 (88.9)

Female, n (%)

411 (57.4)

83 (60.1)

45 (62.5)

59 (72.8)

85 (70.2)

24 (61.5)

21 (56.8)

26 (54.2)

28 (48.3)

9 (37.5)

25 (56.8)

6 (11.1)

APOE ε4–/–, n (%)

506 (70.7)

93 (67.4)

49 (68.1)

65 (80.2)

88 (72.7)

29 (74.4)

25 (67.6)

32 (66.7)

40 (69.0)

19 (79.2)

31 (70.5)

35 (64.8)

APOE ε4+/–, n (%)

190 (26.5)

41 (29.7)

20 (27.8)

14 (17.3)

32 (26.4)

10 (25.6)

10 (27.0)

15 (31.3)

16 (27.6)

5 (20.8)

11 (25.0)

16 (29.6)

APOE ε4+/+, n (%)

20 (2.8)

4 (2.9)

3 (4.2)

2 (2.5)

1 (0.8)

0 (0.0)

2 (5.4)

1 (2.1)

2 (3.4)

0 (0.0)

2 (4.5)

3 (5.6)

CSF Aβ42 assay and concentrations measured (ng/L), mean (SD)

 

xMAP Luminex AlzBio3

xMAP Luminex AlzBio3

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

xMAP Luminex AlzBio3

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

INNOTEST β-amyloid[1–42]

 All genotypes

252.1 (71.0)

257.7 (57.7)

255.1 (54.2)

260.2 (91.5)

250.8 (75.8)

260.3 (67.6)

245.4 (58.7)

250.3 (39.8)

242.2 (71.9)

247.6 (72.3)

259.0 (92.4)

232.1 (84.6)

APOE ε4–/–

261.2 (70.9)

264.6 (57.2)

259.8 (51.7)

262.5 (93.9)

264.0 (68.2)

260.8 (66.0)

257.5 (66.2)

258.3 (36.8)

258.5 (75.0)

260.9 (72.9)

276.6 (89.1)

240.6 (93.0)

APOE ε4+/–

234.8 (65.4)

250.5 (51.4)

245.3 (63.1)

266.4 (76.0)

219.7 (82.5)

258.9 (75.7)

220.3 (29.0)

241.7 (31.4)

205.4 (52.2)

197.0 (46.3)

230.0 (90.4)

216.0 (66.6)

APOE ε4+/+

185.5 (59.0)

172.0 (67.9)

243.3 (21.1)

139.3 (24.6)

87.5 (N/A)

N/A

219.2 (13.4)

125.7 (N/A)

209.7 (10.0)

N/A

143.9 (31.5)

218.0 (75.1)

  1. APOE apolipoprotein E, Aβ42 beta-amyloid1–42, CSF cerebrospinal fluid, SD standard deviation, N/A not available